Santhera Provides Update on Convertible Bond Issued on 23 September 2025

Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical needs [2] - The company has an exclusive license for AGAMREE® (vamorolone), a dissociative steroid, which is approved for treating Duchenne muscular dystrophy (DMD) in multiple regions including the U.S., EU, UK, China, and Hong Kong [2] Convertible Bond Update - The conversion price for the newly announced convertible bond is set at CHF 13.5446, which represents a 10% premium to the volume-weighted average price (VWAP) of Santhera's shares on 23 September 2025 [6] - The coupon rate for the bond is 7%, indicating a reduction compared to the previous bond [6] - The total principal amount of the convertible bond, including the exchange at parity of the prior bond, is CHF 20.132 million [6]